This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pai-Scherf, L. H. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Pai-Scherf, L. H. Articles by Pastan, I.

Hepatotoxicity in Cancer Patients Receiving erb-38, a Recombinant Immunotoxin That Targets the erbB2 Receptor

Laboratory of Molecular Biology, Division of Basic Sciences [L. H. P-S., I. P.], and Laboratory of Molecular Signaling and Oncogenesis [J. V., E. L.] and Medicine Branch [D. P., T. W.], Division of Clinical Sciences National Cancer Institute, NIH, Bethesda, Maryland 20892; and Department of Pathology, Wake Forest University, Winston-Salem, North Carolina 27157 [M. C. W.]

	ABSTRACT

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
To exploit overexpression of erbB2 in human cancers, we constructed a single-chain immunotoxin (erb-38) that contains the Fv portion of monoclonal antibody e23 fused to a truncated form of Pseudomonas exotoxin A. In a Phase I study, five breast cancer patients and one esophageal cancer patient received three doses of erb-38 at 1.0 and 2.0 µg/kg. Hepatotoxicity was observed in all patients. Immunohistochemistry showed the presence of erbB2 on hepatocytes explaining the liver toxicity of erb-38. We suggest that targeting of tumors with antibodies to erbB2 armed with radioisotopes or other toxic agents may result in unexpected organ toxicities due to erbB2 on normal cells.

	Introduction

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
erbB2/HER2/neu encodes an M_r 185,000 cell membrane glycoprotein with tyrosine kinase activity. Overexpression of the erbB2 protein and its inherent tyrosine kinase activity causes loss of growth control and has an important role in the development of breast cancer and several other human cancers (1, 2, 3) . erbB2 has been reported previously to be minimally expressed in normal adult tissues (4) . For this reason, erbB2 is an attractive target for antibody-directed therapies. To exploit the overexpression of erbB2 in many human cancers (breast, stomach, lung, and ovary), we made a single-chain immunotoxin erb-38 using MAb² e23 (5) , which reacts with erbB2.

erb-38 is a M_r 63,000 recombinant protein composed of the Fv portion of MAb e23 fused to PE38, a truncated form of PE with a molecular weight of 38,000. MAb e23 was selected from a panel of antibodies to erbB2 because it produced very active conventional immunotoxins when it was chemically linked to PE (6) . PE is a M_r 66,000 protein secreted by Pseudomonas aeruginosa. PE is composed of three major structural domains (7) : an NH₂-terminal cell binding domain (domain Ia), a central translocation domain (domain II), and a COOH-terminal catalytically active domain (domain III). Domain III catalyzes the ADP ribosylation and inactivation of elongation factor 2, which inhibits protein synthesis and leads to cell death. Deletion of domain Ia of PE (amino acids 1–252) and part of domain Ib produces a M_r 38,000 protein (PE38) that has low cellular and animal cytotoxicity because it cannot bind to PE-specific cellular receptors. The gene encoding PE38 was fused to a gene encoding the Fv portion of MAb e23 to form erb-38 [e23(dsFv)PE38]. In this recombinant immunotoxin, the Fv fragment contains a disulfide bond connecting the light and heavy chains of MAb e23 (8) . The IC₅₀ of erb-38 is 0.2–4 ng/ml on the various tumor cells lines that express the erbB2 antigen. erb-38 is capable of causing complete remission in nude mice bearing epidermoid carcinoma (A431) and breast cancer (MCF-7; Ref. 9 ). Preclinical toxicity experiments indicated that the LD₅₀ of erb-38 in mice was 450 µg/kg every other day times three doses. Death was caused by acute hepatic necrosis. Hepatic and renal injury was observed in cynomolgus monkeys at three doses of 500 µg/kg.³

On the basis of the biological activity and safety testing results, we concluded that erb-38 had excellent antitumor activity and acceptable animal toxicities. We initiated a Phase I study of erb-38 in patients with advanced carcinoma who had failed standard therapy.

	Patients and Methods

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
Eligibility.
Adult patients with metastatic carcinoma known to express erbB2 were eligible for this study. Tumors were considered positive if they expressed erbB2 on 30% of the tumor cells, as determined by immunohistochemistry on formaldehyde-fixed, paraffin-embedded tumor blocks. Tumor histology was confirmed by a NIH pathologist. Other eligibility criteria included: advanced unresectable disease, failed conventional therapy, Eastern Cooperative Oncology Group performance status of 0 or 1, AST and ALT levels of <1.5 times the upper limits of normal, total bilirubin levels within normal limits, absolute granulocyte counts of >2,000/mm³, and platelet counts of >100,000/mm³. Patients with positive hepatitis B antigen, history of any other prior liver disease (e.g., alcohol liver disease), central nervous system metastasis, or seizure disorders were excluded. Patients with positive antibodies to erb-38 were excluded. The clinical protocol and the consent form were approved by the Institutional Review Board of the NCI. Prior to therapy, patients underwent complete physical examination, complete blood count, determination of chemistry profile, urinalysis, chest X-ray, electrocardiogram, tumor staging work-up, and tumor measurement. Informed consent was obtained from all patients.

erb-38.
erb-38 (NSC 683039) was produced and placed in vials by NCI-Frederick Cancer Research & Development Center. erb-38 was supplied through the Cancer Therapy Evaluation Program, NCI, under Investigational New Drug No. 7373. erb-38 in phosphate buffer solution was supplied as a sterile solution at 0.5 mg/ml in 2-ml vials containing 1.0 mg of erb-38. Test and treatment doses were diluted in 0.9% normal saline and 0.2% albumin.

Trial Design.
erb-38 was administered by i.v. infusion over 30 min on days 1, 3, and 5. All patients received a 10-µg test dose on day 1 given as a bolus over 2 min. The second and third doses were delayed or withheld if any measure of toxicity was not less than grade II on the scheduled day of administration. A cycle could be repeated every 28 days, provided that the patient had not developed neutralizing antibodies against erb-38 and had no disease progression. Patients were to be entered in groups of three. Dose escalation was to based on the modified Fibonacci series.

While on study, patients were followed with complete blood count, blood chemistry and urine. Tumor imaging was repeated 1 month after therapy. Toxicity and response to treatment were graded by the NCI Common Toxicity Criteria. Limiting toxicity was defined as any grade III or grade IV toxicity.

Pharmacokinetics.
Blood samples were collected at the following times for pharmacokinetics: pretreatment; 2, 15, 30, 45, 60, and 90 min; and 2, 4, 8, 12, 24, and 48 h. After the second and third doses of erb-38, samples were collected at 2 min, 30 min, and 4 h. The concentration of erb-38 was determined by incubating various dilutions of serum with N87 cells, a gastric cancer cell line known to express erbB2, and measuring its ability to inhibit protein synthesis. A standard curve was used to determine the amount of erb-38 in each sample. Data were weighted inversely, and the fit program used was RSTRIP (MicroMath Scientific Inc., Salt Lake City, UT).

Immunogenicity of erb-38.
Antibodies against erb-38 were assessed pretreatment, on day 21, and then bimonthly thereafter by a serum neutralization assay: erb-38 was added to serum samples at 0.0 (control), 0.1, 0.5, and 1.0 µg/ml and incubated at 37°C for 15 min. The activity of erb-38 was assayed by incubating the samples with MCF-7 cells and measuring its ability to inhibit protein synthesis. A standard curve with erb-38 was used to determine IC₅₀. A serum sample was considered negative for antibodies against erb-38 when the cytotoxic activity of erb-38 was not neutralized when incubated with sera at concentrations of >0.1 µg/ml erb-38.

Immunohistochemistry of Normal Liver.
Fresh normal human liver samples were frozen by immersion in liquid nitrogen. Cryostat sections (6 µm) were thaw-mounted on slides and fixed in 3.7% formaldehyde in PBS for 10 min at 23°C, followed by washing in PBS. Sections were not treated with H₂O₂ or any organic solvents. After blocking in 1% BSA in PBS for 10 min, sections were incubated in mouse monoclonal anti-erbB2 (CB11; Novocastra Laboratories, Novocastra antibody, Vector Laboratories, Burlingame, CA) at 10 µg/ml in BSA-PBS for 30 min at 23°C. Alternatively, sections were incubated in affinity-purified rabbit anti-erbB2 (code A 0485; Dako Corporation, Carpinteria, CA) at 7 µg/ml in BSA-PBS. After further washing in PBS, sections were incubated, as appropriate, with either goat antimouse IgG or goat antirabbit IgG conjugated with horseradish peroxidase (Jackson ImmunoResearch) at 25 µg/ml in BSA-PBS for 30 min. Peroxidase was detected using diaminobenzidine (1 ng/ml) with 0.01% H₂O₂ in PBS for 10 min. Controls included deletion of the first antibody step. Sections were mounted using dehydration and Permount without further counterstains and viewed using bright-field microscopy.

	Results

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
Six patients were enrolled in this trial. Patient characteristics are shown in Table 1 . The initial dose level was 2 µg/kg times three, which was 1/250 of the MTD in monkeys and 1/225 of the LD₅₀ in mice. This conservative starting dose was chosen due to the fact that the toxicity of immunotoxins in humans has thus far been found to be unpredictable. Furthermore, 2.0 µg/kg times three has been shown to be safe with two other recombinant immunotoxins made with PE (LMB-7 and LMB-2).³

View larger version (15K): [in this window] [in a new window]   Fig. 1. Time course of AST () and ALT (•) of patient 2, who received 2.0 µg/kg (A) and patient 5, who received 1.0 µg/kg erb-38 (B).

Localization of erbB2 in Normal Liver.
Although prior literature had suggested that erbB2 was not expressed in normal liver (4) , we used a sensitive immunohistochemical method with antibodies to erbB2 that were not available until recently. Rapidly frozen normal human liver samples were sectioned with a cryostat and postfixed using formaldehyde but were not exposed to H₂O₂ or any organic solvents. Mouse monoclonal CB11 and rabbit polyclonal A0485 were used for the detection of erbB2 using affinity-purified antiglobulins labeled with horseradish peroxidase. When viewed without counterstains, the localization of erbB2 to the sinusoidal surface of normal hepatocytes was clearly visible using either primary antibody (CB11 and AD485; Fig. 2 ). The same result was observed from samples of normal liver derived from at least three different patients. Similar results were also obtained with antibody E23 (data not shown).

View larger version (177K): [in this window] [in a new window]   Fig. 2. Localization of erbB2 to the surface of normal human hepatocytes. Frozen sections of normal human liver were incubated with either a mouse MAb to erbB2 (CB11; B) or a rabbit polyclonal affinity-purified anti-erbB2 (A0485; D). Corresponding controls with deletion of the first step but with the second step included are shown for antimouse IgG (A) or antirabbit IgG (C). The characteristic pattern, especially at intercellular junctions, of the sinusoidal surface of hepatocytes is evident (arrows) with both antibodies (B and D). These sections were not counterstained, and the nuclear localization seen in D represents a nonspecific pattern seen only with the rabbit anti-erbB2 antibody. (Magnification, x375; scale bar, 50 µm).

Immunogenicity.
Patients had no neutralizing antibodies against erb-38 prior to therapy, as required by protocol. At the end of one cycle, only one patient (patient 3) developed neutralizing antibodies (>1.0 µg/ml) against erb-38 14 days after treatment. Retreatment was not possible in this patient, due to disease progression.

Response.
No objective responses were observed in the trial. One patient had stable disease for 3 months, four patients progressed after one cycle of therapy, and one patient was not evaluable for response. Patient 2 had improvement of chest wall pain after erb-38 that lasted for 3 weeks. Fentanyl transdermal patch requirement decreased from 225 to 25 µg/h in this patient.

	Discussion

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 
We have shown that, when a recombinant immunotoxin, erb-38, which targets erbB2, is given to cancer patients, it causes hepatic injury, manifested by transient elevation of transaminases. The dose-limiting toxicities of erb-38 occurred at 1.0 and 2.0 µg/kg when it was given i.v. every other day times three. These doses are significantly below the doses necessary to show antitumor effects in animals. Although the MTD was not determined, based on our preclinical experience with this agent, effective serum levels cannot be achieved at doses <1.0 µg/kg (6) . In addition, we found that the erb-38 was cleared monoexponentially from the circulation, with a T_1/2 that varied from 2.4 to 10.3 h. As compared with other biological agents of this nature, a great deal of variation was observed from patient to patient. At 2.0 µg/kg, the maximum concentration varied from <20 to 105 ng/ml. No clear correlation can be made between the pharmacokinetic findings and the tumor burden, toxicity, or expression of erb-38 on tumor cells (all patients had tumors that expressed erbB2 on 80% of the cells).

The toxicity of erb-38 is most likely due to the presence of erbB2 on hepatocytes, not detected by immunohistochemical staining in earlier publications (4) . We have now repeated these assays using newly available antibody to erbB2 (affinity-purified rabbit anti-erbB2, code A 0485; Dako Corp.) and have shown here that erbB2 is clearly present on the surface of normal hepatocytes. The expression of erbB2 is known to be very high in 30% of breast cancers, often due to gene amplification. Despite the fact that there is a very large difference in the amount of erbB2 on the surface of cancer cells relative to the small amount present on liver cells, liver toxicity was the first biological effect seen in this study. Several factors contribute to this finding. One is that hepatocytes are more rapidly exposed to agents injected into the circulation than tumor cells. There is a barrier to proteins entering tumors because tumors do not have lymphatics and there is no connective flow. As a consequence, mixing within tumors is solely by diffusion and, therefore, very slow. In addition, tumors are often poorly vascularized (10) .

There are several ways in which antibodies are being used as antitumor agents. Antibodies have been used by themselves to produce antitumor activity, taking advantage of their ability to carry out complement-mediated cell killing or ADCC (antibody dependent cell- and complement-mediated cytotoxicity) or to induce apoptosis directly. One or more of these effects explains how Rituximab, which binds to CD20, causes regression of lymphomas (11) . Recently, clinical data concerning the safety and efficacy of a humanized antibody to erbB2 termed Herceptin were presented (12 , 13) . The antibody alone has been found to produce objective responses in breast cancer and when combined with chemotherapy results in an increased response rate. It is likely that the antitumor activity of the antibody in this setting is dependent on genetic perturbations that alter the configuration of downstream signaling events, and, thereby, the responsiveness of the cancer cells to Herceptin. Thus, the mechanism of killing depends on a genetic abnormality present in the cancer cells. In contrast, if the antibody is used to deliver a cytotoxic agent, such as a bacterial toxin or radioisotope, the death of the target cell will be principally dependent on the amount of agent delivered to the cell. In the case of erb-38, it appears that liver cells are the initial site of drug action. It has also been found in the Herceptin trial that there is evidence of cardiotoxicity, perhaps due to the presence of small amounts of erbB2 on myocytes or endocardial cells. Unfortunately, the information concerning the cardiotoxicity of Herceptin was not yet reported at the time of this trial. We did not include a throughout cardiac evaluation with echocardiogram or MUGA (Multigated Radionuclide Angiography) scan in the initial work-up. However, none of the patients had clinical evidence of myocardial dysfunction or arrhythmia before or after therapy with erb-38 based on their history, physical exam, chest X-ray, and electrocardiogram. It is quite possible that, because the concentrations of erb-38 given were low, overt cardiotoxicity was detected in this small trial. This might have been observed if higher doses of erb-38 had been administered.

The new findings of reactivity with anti-erbB2 antibodies on hepatocytes are, for the most part, the result of the availability of the affinity-purified rabbit anti-erbB2. With this antibody, which has been shown to be 2–4-fold more sensitive in detecting erbB2 in paraffin sections of breast tumors, we were able to evaluate carefully the conditions used for histochemistry to optimize localization of erbB2 in breast cancer specimens. With these new conditions, which include the use of frozen sections of freshly frozen tissues, formaldehyde postsectioning fixation, the deletion of treatments with any peroxide or organic solvents, and the deletion of counterstains, the localization of erbB2 was optimal in tumor specimens as well as in normal human liver. These results allowed us to go back and test previously available monoclonal antibodies, such as CB11 and E23, both of which also showed specific surface labeling at a low level in hepatocytes. As shown in Fig. 2 , this labeling was homogeneous, surface related, and absent in parallel controls for all of the antibodies, implying that it was truly specific for erbB2.

Two other recombinant immunotoxins developed by our group have recently been evaluated in Phase 1 trials. Both can be given at much higher doses than erb-38. One of these is LMB-7 [B3(Fv)PE38], which targets a carbohydrate antigen present in colon, breast, and other epithelial cancers (14) . The MTD of LMB-7 was found to be 24 µg/kg when given every other day times three. The dose-limiting toxicities were nausea, vomiting and diarrhea, secondary to the targeting of the carbohydrate antigen present on the gastric mucosa.⁴ LMB-2 [anti-Tac(Fv)PE38] is a recombinant immunotoxin that targets CD25 (15) , the -subunit of the interleukin 2 receptor. In patients with leukemia and lymphoma, the MTD was 40 µg/kg, at which several clinical responses have been observed.⁵

We conclude that the toxicity observed with erb-38 is most likely due to the presence of erbB2 on hepatocytes. The targeting of tumors with antibodies to erbB2 that are armed with radioisotopes and other toxic agents may result in unexpected organ toxicities due to erbB2 expression on normal tissues.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Laboratory of Molecular Biology, National Cancer Institute, NIH, 37 Convent Drive, MSC 4255, Bethesda, MD 20892-4255. Phone: (301) 496-4797; Fax: (301) 402-1344; E-mail: pasta{at}helix.nih.gov

² The abbreviations used are: MAb, monoclonal antibody; PE, Pseudomonas exotoxin A; AST, aspartate aminotransferase; ALT, alanine aminotransferase; NCI, National Cancer Institute; MTD, maximum tolerated dose.

³ Unpublished data.

⁴ L. H. Pai-Scherf and I. Pastan, manuscript in preparation.

⁵ R. J. Kreitman, T. Waldmann, and I. Pastan, manuscript in preparation.

Received 2/18/99; revised 5/14/99; accepted 5/26/99.

	REFERENCES

Top ABSTRACT Introduction Patients and Methods Results Discussion REFERENCES

 

1. Slamon D., Godolphim W., Jones L. A., Holt J. A., Wong S. B., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. F. Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.[Abstract/Free Full Text]
2. Schneider P. M., Hung M. C., Chiocca S. M., Manning J., Zhao X. Y., Fang K., et al Differential expression of the erbB2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49: 4968-4971, 1989.[Abstract/Free Full Text]
3. Park J., Rhim J. S., Park S. C., Kimm S. W., Kraus M. H. Amplification, overexpression and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res., 49: 6605-6609, 1989.[Abstract/Free Full Text]
4. Press M. F., Cordon-Cardo C., Slamon D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.[Medline]
5. Kasprzyk P. G., Song S. V., DiFiore P. P., King C. R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB2 monoclonal antibodies. Cancer Res., 52: 2771-2776, 1992.[Abstract/Free Full Text]
6. Reiter Y., Brinkmann U., Jung S-H., Pastan I., Lee B. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide Stabilization of the Fv fragment. J. Biol. Chem., 269: 18327-18331, 1994.[Abstract/Free Full Text]
7. Allured V. S., Collier R. J., Carroll S. F., McKay D. B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 angstrom resolution. Proc. Natl. Acad. Sci. USA, 83: 1320-1324, 1986.[Abstract/Free Full Text]
8. Reiter Y., Brinkmann U., Kreitman R., Jung S-H., Lee B., Pastan I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry, 33: 5451-5459, 1994.[Medline]
9. Reiter Y., Pastan I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin. Cancer Res., 2: 245-252, 1998.[Abstract/Free Full Text]
10. Jain R. K. Delivery of novel therapeutic agents in tumors: physiological Barriers and strategies. J. Natl. Cancer Inst., 8: 570-576, 1989.
11. Maloney D. G., Grillo-Lopes A. J., Bodkin D, White C. A., Liles T. M., Royston I. IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood, 90: 2188-2195, 1997.[Abstract/Free Full Text]
12. Cobleigh M. A., Vogel C. L., Tripathy N. J., Tripathy D., Robert N. J., Scholl S., Fehrenbacher L., Paton V., Shak S., Lieberman G., Slamon D. Efficacy and safety of Herceptin (humanized anti-Her2 antibody) as a single agent in 222 humans with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., Abstract 376: 97a 1998.
13. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Baselga, J., and Norton, L. Addition of Herceptin (humanized anti-Her2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HEr2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol., Abstract 397, 98a, 1998.
14. Pai L. H., Pastan I. Immunotoxin therapy for cancer. J. Am. Med. Assoc., 269: 78-81, 1993.[Medline]
15. Kreitman R. J., Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol., 6: 297-306, 1995.[Medline]

This article has been cited by other articles:

				X.-C. Qiu, Y.-M. Xu, F. Wang, Q.-Y. Fan, L.-F. Wang, B.-A. Ma, L.-T. Jia, J. Zhao, Y.-L. Meng, L.-B. Yao, et al. Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth Mol. Cancer Ther., July 1, 2008; 7(7): 1890 - 1899. [Abstract] [Full Text] [PDF]

				B. J. Stish, H. Chen, Y. Shu, A. Panoskaltsis-Mortari, and D. A. Vallera Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv Clin. Cancer Res., May 15, 2007; 13(10): 3058 - 3067. [Abstract] [Full Text] [PDF]

				Z. Li, S. P. Mahesh, D. F. Shen, B. Liu, W. O. Siu, F. S. Hwang, Q.-C. Wang, C.-C. Chan, I. Pastan, and R. B. Nussenblatt Eradication of Tumor Colonization and Invasion by a B Cell-Specific Immunotoxin in a Murine Model for Human Primary Intraocular Lymphoma Cancer Res., November 1, 2006; 66(21): 10586 - 10593. [Abstract] [Full Text] [PDF]

				P. M. Weinberger, Z. Yu, D. Kowalski, J. Joe, P. Manger, A. Psyrri, and C. T. Sasaki Differential Expression of Epidermal Growth Factor Receptor, c-Met, and HER2/neu in Chordoma Compared With 17 Other Malignancies Arch Otolaryngol Head Neck Surg, August 1, 2005; 131(8): 707 - 711. [Abstract] [Full Text] [PDF]

				R. B. Michel, P. M. Andrews, M. E. Castillo, and M. J. Mattes In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2 Mol. Cancer Ther., June 1, 2005; 4(6): 927 - 937. [Abstract] [Full Text] [PDF]

				R. J. Kreitman Confirmation and prevention of targeted toxicity by a recombinant fusion toxin Mol. Cancer Ther., December 1, 2004; 3(12): 1691 - 1692. [Full Text] [PDF]

				S. M. Thomas, Q. Zeng, M. W. Epperly, W. E. Gooding, I. Pastan, Q. C. Wang, J. Greenberger, and J. R. Grandis Abrogation of Head and Neck Squamous Cell Carcinoma Growth by Epidermal Growth Factor Receptor Ligand Fused to Pseudomonas Exotoxin Transforming Growth Factor {alpha}-PE38 Clin. Cancer Res., October 15, 2004; 10(20): 7079 - 7087. [Abstract] [Full Text] [PDF]

				M. Onda, Q.-c. Wang, H.-f. Guo, N.-K. V. Cheung, and I. Pastan In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma Cancer Res., February 15, 2004; 64(4): 1419 - 1424. [Abstract] [Full Text] [PDF]

				S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound Clin. Cancer Res., November 15, 2003; 9(15): 5776 - 5785. [Abstract] [Full Text] [PDF]

				A. E. Frankel, B. L. Powell, P. D. Hall, L. D. Case, and R. J. Kreitman Phase I Trial of a Novel Diphtheria Toxin/Granulocyte Macrophage Colony-stimulating Factor Fusion Protein (DT388GMCSF) for Refractory or Relapsed Acute Myeloid Leukemia Clin. Cancer Res., May 1, 2002; 8(5): 1004 - 1013. [Abstract] [Full Text] [PDF]

				A. E. Frankel Increased Sophistication of Immunotoxins Clin. Cancer Res., April 1, 2002; 8(4): 942 - 944. [Full Text] [PDF]

				N. Takahashi, A. Haba, F. Matsuno, and B. K. Seon Antiangiogenic Therapy of Established Tumors in Human Skin/Severe Combined Immunodeficiency Mouse Chimeras by Anti-Endoglin (CD105) Monoclonal Antibodies, and Synergy between Anti-Endoglin Antibody and Cyclophosphamide Cancer Res., November 1, 2001; 61(21): 7846 - 7854. [Abstract] [Full Text] [PDF]

				Y. Tsutsumi, M. Onda, S. Nagata, B. Lee, R. J. Kreitman, and I. Pastan Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity PNAS, July 18, 2000; 97(15): 8548 - 8553. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pai-Scherf, L. H. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Pai-Scherf, L. H. Articles by Pastan, I.